Distinction between mild cognitive impairment and Alzheimer's disease by CSF amyloid β40 and β42, and protein-conjugated acrolein

Clinica Chimica Acta

Volumn 430, Issue , 2014, Pages 150-155

  Mizoi, Mutsumi ^a   Yoshida, Madoka ^a   Saiki, Ryotaro ^a   Waragai, Masaaki ^b   Uemura, Kenichi ^b   Akatsu, Hiroyasu ^c   Kashiwagi, Keiko ^d   Igarashi, Kazuei ^a  

^a CHIBA UNIVERSITY   (Japan)

^b Higashimatsudo Hospital   (Japan)

^c Fukushimura Hospital   (Japan)

^d CHIBA INSTITUTE OF SCIENCE   (Japan)

Author keywords

Alzheimer's disease; CSF Amyloid ; Magnetic resonance imaging; MCI; MMSE; Protein conjugated acrolein

Indexed keywords

ACROLEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BIOACCUMULATION; BRAIN ATROPHY; BRAIN DAMAGE; BRAIN LEVEL; BRAIN REGION; BRAIN TISSUE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DISEASE SEVERITY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; CEREBROSPINAL FLUID; VERY ELDERLY;

ACROLEIN; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; PEPTIDE FRAGMENTS;

EID: 84896737480     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.01.007     Document Type: Article

References (33)

1. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
2. Drachman D.A. Aging of the brain, entropy, and Alzheimer disease. Neurology 2006, 67:1340-1352.
3. Nordberg A., Rinne J.O., Kadir A., Langstrom B. The use of PET in Alzheimer disease. Nat Rev Neurol 2010, 6:78-87.
4. Risacher S.L., Shen L., West J.D., et al. Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort. Neurobiol Aging 2010, 31:1401-1418.
5. Sobow T., Flirski M., Kloszewska I., Liberski P.P. Plasma levels of Ab peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. Acta Neurobiol Exp (Wars) 2005, 65:117-124.
6. Roher A.E., Esh C.L., Kokjohn T.A., et al. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement 2009, 5:18-29.
7. Le Bastard N., Leurs J., Blomme W., De Deyn P.P., Engelborghs S. Plasma amyloid-b forms in Alzheimer's disease and non-Alzheimer's disease patients. J Alzheimers Dis 2010, 21:291-301.
8. Lui J.K., Laws S.M., Li Q.X., et al. Plasma amyloid-b as a biomarker in Alzheimer's disease: the AIBL study of aging. J Alzheimers Dis 2010, 20:1233-1242.
9. Yaffe K., Weston A., Graff-Radford N.R., et al. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 2011, 305:261-266.
10. Devanand D.P., Schupf N., Stern Y., et al. Plasma Ab and PET PiB binding are inversely related in mild cognitive impairment. Neurology 2011, 77:125-131.
11. Calingasan N.Y., Uchida K., Gibson G.E. Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease. J Neurochem 1999, 72:751-756.
12. Bradley M.A., Markesbery W.R., Lovell M.A. Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease. Free Radic Biol Med 2010, 48:1570-1576.
13. Dang T.N., Arseneault M., Murthy V., Ramassamy C. Potential role of acrolein in neurodegeneration and in Alzheimer's disease. Curr Mol Pharmacol 2010, 3:66-78.
14. 40/42 ratio in plasma of patients with mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 2012, 32:33-41.
15. Schoonenboom N.S., van der Flier W.M., Blankenstein M.A., et al. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. Neurobiol Aging 2008, 29:669-675.
16. 42 correlates with brain atrophy in cognitively normal elderly. Ann Neurol 2009, 65:176-183.
17. Tapiola T., Alafuzoff I., Herukka S.K., et al. Cerebrospinal fluid b-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009, 66:382-389.
18. de Souza L.C., Chupin M., Lamari F., et al. CSF tau markers are correlated with hippocampal volume in Alzheimer's disease. Neurobiol Aging 2012, 33:1253-1257.
19. 1-42 and t proteins as Alzheimer disease biomarkers. Clin Chem 2013, 59:903-916.
20. Hansson O., Zetterberg H., Buchhave P., et al. Prediction of Alzheimer's disease using the CSF Ab42/Ab40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 2007, 23:316-320.
21. Waragai M., Okamura N., Furukawa K., et al. Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimer's disease. J Neurol Sci 2009, 285:100-108.
22. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
23. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999, 56:303-308.
24. Tomitori H., Usui T., Saeki N., et al. Polyamine oxidase and acrolein as novel biochemical markers for diagnosis of cerebral stroke. Stroke 2005, 36:2609-2613.
25. Igarashi K., Ueda S., Yoshida K., Kashiwagi K. Polyamines in renal failure. Amino Acids 2006, 31:477-483.
26. Igarashi K., Kashiwagi K. Protein-conjugated acrolein as a biochemical marker of brain infarction. Mol Nutr Food Res 2011, 55:1332-1341.
27. Gao S., Hendrie H.C., Hall K.S., Hui S. The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. Arch Gen Psychiatry 1998, 55:809-815.
28. Hirata Y., Matsuda H., Nemoto K., et al. Voxel-based morphometry to discriminate early Alzheimer's disease from controls. Neurosci Lett 2005, 382:269-274.
29. Uchida K., Kanematsu M., Morimitsu Y., Osawa T., Noguchi N., Niki E. Acrolein is a product of lipid peroxidation reaction. Formation of free acrolein and its conjugate with lysine residues in oxidized low density lipoproteins. J Biol Chem 1998, 273:16058-16066.
30. Tomitori H., Nakamura M., Sakamoto A., et al. Augmented glutathione synthesis decreases acrolein toxicity. Biochem Biophys Res Commun 2012, 418:110-115.
31. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
32. Wu B., Kitagawa K., Zhang N.Y., Liu B., Inagaki C. Pathophysiological concentrations of amyloid b proteins directly inhibit rat brain and recombinant human type II phosphatidylinositol 4-kinase activity. J Neurochem 2004, 91:1164-1170.
33. Yagyu K., Kitagawa K., Irie T., et al. Amyloid b proteins inhibit Cl-ATPase activity in cultured rat hippocampal neurons. J Neurochem 2001, 78:569-576.